DMDiana O. Mokrousova

Diana O. Mokrousova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Diana O. Mokrousova has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Whole Tumor Cells and Their Derivatives for the Development of Therapeutic Cancer Vaccines

    by Diana Mokrousova, Anna Efremova, Margarita Maiak, Tatiana Budagova, Asya Bastrich, Dmitry Goldshtein

    One approach to therapeutic cancer vaccine development uses whole tumor cells or their lysates as sources of a broad repertoire of tumor antigens. A key advantage of this strategy is that it does not require prior identification of tumor antigens, unlike personalized neoantigen peptide or mRNA vaccines, potentially reducing the time and cost of vaccine development. However, late-phase clinical trials have not demonstrated sufficient efficacy of tumor cell-based cancer vaccines. Currently, strategies to enhance the therapeutic potential of vaccines based on whole tumor cells and their derived lysates are being actively developed, and the vaccine potential of individual tumor cell components, such as cell membranes and extracellular vesicles, is under investigation. In this review, we systematize data on how whole tumor cells and their derivatives (lysates, cell membranes, and extracellular vesicles) are used to generate therapeutic cancer vaccines, analyze the results of experimental and clinical studies, and evaluate promising engineering and combination therapy strategies capable of overcoming the current limitations of this platform.

  • Open Access

    iPSC-Derived T and CAR-T Cells of Distinct Phenotypes: Current Protocols, Challenges and Potential for Cancer Treatment

    by Margarita Maiak, Anna Efremova, Tatiana Budagova, Diana Mokrousova, Dmitry Goldshtein

    Adoptive T-cell therapy has demonstrated substantial clinical efficacy in several hematological malignancies, but autologous manufacturing remains limited by variability in starting cell material, manufacturing time, product heterogeneity, and T-cell dysfunction. Induced pluripotent stem cells (iPSCs) provide a potentially scalable and genetically engineerable source for the generation of standardized allogeneic T-cell products. This review summarizes current approaches to the differentiation of iPSCs into distinct T-cell phenotypes and evaluates their potential for cancer immunotherapy. We first discuss iPSC-derived conventional αβ T cells, including recent advances in feeder-free and scalable differentiation, maturation, and genetic engineering, as well as preclinical and early clinical evidence. We then examine γδ T cells, invariant natural killer T cells, and mucosal-associated invariant T cells, focusing on their distinctive antigen-recognition mechanisms, effector functions, tissue tropism, differentiation strategies, and therapeutic applications. Across these populations, iPSC technology may facilitate standardized and scalable production while enabling targeted engineering of T-cell specificity and functional properties. However, important challenges remain, including efficient lineage-specific differentiation, maturation, phenotypic consistency, long-term persistence, tumor infiltration, and control of alloreactivity and immunogenicity. Overall, iPSC-derived T cells represent a versatile platform for developing diverse cellular immunotherapies, although their clinical potential remains dependent on further technological and translational advances.

  • Open Access

    A comprehensive study of a rare pathogenic CFTR gene variant G1047S in two siblings

    by D. O. Mokrousova, A. S. Efremova, Yu. L. Melyanovskaya, A. Yu. Voronkova, S. A. Krasovskiy, M. G. Krasnova, N. V. Rassomahina, T. B. Bukharova, O. V. Makhnach, D. V. Goldshtein, et al.

    Most of the known pathogenic variants of the CFTR gene are rare. Studying these variants allows us to gain new knowledge about the pathogenesis of cystic fibrosis, assess the variability of its manifestations among patients, and optimize therapeutic approaches.   The aim was to comprehensively study a rare variant of the CFTR gene G1047S (c.3139G>A, p.(Gly1047Ser)) in two siblings, including a description of the clinical picture, functional assessment of the CFTR channel ex vivo by determining the intestinal current measurement (ICM) and the forskolin-induced swelling (FIS) assay of the effect of CFTR modulators in vitro in the intestinal organoids.   Methods. The case history was presented. The ICM was used to study membrane channels of the intestinal epithelium. The FIS assay in the intestinal organoids of the patients was used to assess the sensitivity of the G1047S variant to ivacaftor, lumacaftor, tezacaftor, and elexacaftor.   Results. The missense variant G1047S is pathogenic but “mild” since the residual CFTR function is observed. The results of functional tests are consistent with the clinical picture: the siblings have pancreatic sufficiency, no nutritional deficiency, and a “mild” course of the disease. The ivacaftor + tezacaftor + elexacaftor therapy can be recommended for patients with the G1047S variant since the intestinal organoid model shows restoration of CFTR functional activity.   Conclusion. The G1047S variant is “mild”, but with lower sensitivity to known combination targeted drugs compared to F508del/F508del.

  • Open Access

    Phenotypic diversity of cystic fibrosis:pathogenesis and modifying factors

    by D. O. Mokrousova, A. S. Efremova, N. Yu. Kashirskaya, A. I. Khavkin, D. V. Goldshtein, Н. Ю. Каширская

    Pathogenic variants of the CFTR gene are the initiating and dominant genetic factor determining phenotypic manifestations in cystic fibrosis (CF). CF is a monogenic disease; however, modifier genes that do not cause the disease themselves have a strong influence on the severity of CF. Individual polymorphisms of modifier genes can both exacerbate and attenuate symptoms, explaining the highly variable clinical manifestations in people with the same CFTR genotype.

  • Open Access

    Therapeutic effect of CFTR modulators in cystic fibrosis patients with the 2789+5G>A splice variant in the genotype

    by M. G. Krasnova, A. S. Efremova, Yu. L. Melyanovskaya, S. A. Krasovskiy, D. O. Mokrousova, T. B. Bukharova, N. V. Bulatenko, E. I. Kondratyeva, D. V. Goldshtein, Ю. Л. Мельяновская

    About 13% of all variants causing cystic fibrosis are splice variants of the CFTR gene; at the moment, such variants are not well studied.The aim was to investigate the effect of the splicing variant 2789+5G>A on the phenotypic manifestations of cystic fibrosis and the effectiveness of targeted therapy in an intestinal organoids model in the patients with genotypes 2789+5G>A/L732X and 2789+5G>A/CFTRdele2,3.Methods. The medical history data, intestinal current measurement (ICM), and forskolin-induced swelling assay in the intestinal organoids were used.Results. The clinical features of the course of CF in 2 patients, carriers of the 2789+5G>A variant in a heterozygous state with genetic variants of the CFTR gene of classes I and VII, are presented. Clinical picture: the disease is of moderate severity; the pancreas is sufficient. The ICM method demonstrated the preservation of the chloride channel function. Assays on the cultured organoids obtained from the intestinal tissue showed moderate residual functional activity of the chloride channels. In addition, the 2789+5G>A variant is sensitive to all tested CFTR modulators.Conclusions. The splicing variant 2789+5G>A is characterized by moderate residual functional activity of the CFTR channel and is sensitive to all targeted treatments. However, the most effective CFTR modulator for this genetic variant is tezacaftor.


  • Open Access

    Personalized assessment of the effectiveness of targeted drugs for the treatment of cystic fibrosis in a patient with c.264_268delATATT and c.3139+1G>C rare variants of the CFTR gene

    by Anna S. Efremova, Victoria D. Sherman, Yuliya L. Melyanovskaya, Diana O. Mokrousova, Maria G. Krasnova, Natalya V. Bulatenko, Tatiana B. Bukharova, Oleg V. Makhnach, Andrey A. Alimov, Dmitry V. Goldstein, et al.

    BACKGROUND: When new, most often rare CFTR gene variants, are detected in patients with cystic fibrosis, intestinal organoids are used, which allows for the assessment of the residual functional activity of the CFTR channel and the effect of targeted drugs to determine the possibility of further pathogenetic therapy. Clinical trials of the effectiveness of the targeted drugs in patients with rare CFTR variants are expensive, and patient groups are extremely small. A forskolin-induced swelling assay on a patient’s intestinal organoids allows for a personalized approach when studying rare or even single CFTR variants. AIM: To examine the effect of the CFTR potentiator ivacaftor and the combination of ivacaftor with the CFTR correctors lumacaftor, tezacaftor, and elexacaftor on the restoration of CFTR channel functions on a culture of intestinal organoids obtained from a patient with two rare CFTR variants c.264_268delATATT and c.3139+1GC. MATERIALS AND METHODS: To assess the activity of the CFTR channel, the forskolin-induced swelling assay on organoids and intestinal current measurements on rectal biopsy samples method were used. The clinical picture of a patient with the c.264_268delATATT/c.3139+1GC genotype was described. RESULTS: In vitro, the genetic variants c.264_268delATATT and c.3139+1GC lead to a complete loss of the functional CFTR protein, whereas CFTR modulators do not positively affect and do not lead to the restoration of CFTR function, in contrast from F508del/F508del control. The disease severity in a child is consistent with the results of functional tests. CONCLUSION: Both CFTR variants are classified as “severe” and cause a complete loss of chloride channel activity. No effective CFTR modulators were found for the c.264_268delATATT and c.3139+1GC variants; thus, targeted therapy cannot be recommended to the patient.


  • Open Access

    Functional activity of the CFTR channel in a patient with the [L467F;F508del]/W1310X genotype

    by M. G. Krasnova, D. O. Mokrousova, A. S. Efremova, Yu. L. Melyanovskaya, V. D. Sherman, T. B. Bukharova, D. V. Goldshtein, Ю. Л. Мельяновская

    An important factor influencing the severity of cystic fibrosis (CF) and the effectiveness of treatment is the presence of complex alleles in the CFTR gene ≥ 2 variants in one allele. The influence of such alleles on the manifestations of CF has not been sufficiently studied.The aim of this study was to investigate the effect of the complex allele [L467F;F508del] on the phenotypic manifestations of CF and the efficacy of targeted therapy in an intestinal organoid (IO) model in a patient with the [L467F;F508del]/W1310X genotype.Methods. Methods for determining the difference in intestinal potentials (IDP), the KO method, and the forskolin test are presented using the medical history of a patient with the [L467F;F508del]/ W1310X genotype as an example.Results. The patient was diagnosed with progressive disease with obvious deterioration of pulmonary function. The ORKP method showed the absence of chlorine channel function. An assay with a KO culture from intestinal tissue showed a complete loss of functional activity of the chloride channel. In addition, the complex allele [L467F;F508del] is not sensitive to the effect of all tested CFTR modulators.Conclusion. The complex allele [L467F;F508del] causes a complete loss of functional CFTR protein and is not sensitive to the effect of any of the registered targeted drugs.